Applications of PET in liver imaging

Radiologic Clinics of North America

Volumn 43, Issue 5 SPEC. ISS., 2005, Pages 849-860

  Khandani, Amir H ^a   Wahl, Richard L ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; ALPHA2B INTERFERON; CARBON 11; CONTRAST MEDIUM; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GERMANIUM 68; GERMANIUM DERIVATIVE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE; METHYLCHOLINE C 11; NITROGEN 13; OXALIPLATIN; OXYGEN 15; TRACER; TYROSINE C 11; UNCLASSIFIED DRUG;

BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; GALLBLADDER CARCINOMA; GLUCOSE METABOLISM; HUMAN; IMAGING SYSTEM; LIVER; LIVER CELL CARCINOMA; LIVER INJURY; LIVER METASTASIS; LIVER TUMOR; MEDICAL RESEARCH; METASTASIS; MINIMAL RESIDUAL DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

EID: 23744513093     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2005.05.008     Document Type: Review

References (76)

1. H.G. Joost, and B. Thorens The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members Mol Membr Biol 18 2001 247 256
2. C.L. Ho, S.C. Yu, and D.W. Yeung 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses J Nucl Med 44 2003 213 221
3. W.E. Brant Liver W.R. Webb W.E. Brant C.A. Helms Fundamentals of body CT 2nd edition 1998 WB Saunders Philadelphia 195 212
4. R. Goslin, G. Steele Jr, and N. Zamcheck Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum Dis Colon Rectum 25 1982 749 754
5. G. Steele Jr, and T.S. Ravikumar Resection of hepatic metastases from colorectal cancer: biologic perspective Ann Surg 210 1989 127 138
6. R.L. Zimmerman, M. Burke, and N.A. Young Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration Cancer 96 2002 53 57
7. D. Delbeke, W.H. Martin, and M.P. Sandler Evaluation of benign vs malignant hepatic lesions with positron emission tomography Arch Surg 133 1998 510 515
8. B. Bohm, M. Voth, and J. Geoghegan Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors J Cancer Res Clin Oncol 130 2004 266 272
9. J.V. Vitola, D. Delbeke, and M.P. Sandler Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver Am J Surg 171 1996 21 26
10. R. Hustinx, P. Paulus, and N. Jacquet Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases Ann Oncol 9 1998 397 401
11. T.H. Arulampalam, D.L. Francis, and D. Visvikis FDG-PET for the pre-operative evaluation of colorectal liver metastases Eur J Surg Oncol 30 2004 286 291
12. C. Schiepers, F. Penninckx, and N. De Vadder Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging Eur J Surg Oncol 21 1995 517 522
13. O.A. Ogunbiyi, F.L. Flanagan, and F. Dehdashti Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography Ann Surg Oncol 4 1997 613 620
14. F.G. Fernandez, J.A. Drebin, and D.C. Linehan Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) Ann Surg 240 2004 438 447
15. F.L. Flanagan, F. Dehdashti, and O.A. Ogunbiyi Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer Ann Surg 227 1998 319 323
16. M. Yang, D.R. Martin, and N. Karabulut Comparison of MR and PET imaging for the evaluation of liver metastases J Magn Reson Imaging 17 2003 343 349
17. K. Kinkel, Y. Lu, and M. Both Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis Radiology 224 2002 748 756
18. E.M. Marom, H.P. McAdams, and J.J. Erasmus Staging non-small cell lung cancer with whole-body PET Radiology 212 1999 803 809
19. B. Topal, P. Flamen, and R. Aerts Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases Eur J Surg Oncol 27 2001 175 179
20. T.J. Ruers, B.S. Langenhoff, and N. Neeleman Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study J Clin Oncol 20 2002 388 395
21. A.F. Chatziioannou Molecular imaging of small animals with dedicated PET tomographs Eur J Nucl Med Mol Imaging 29 2002 98 114
22. D. Visvikis, and P.J. Ell Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives Eur J Nucl Med Mol Imaging 30 Suppl 1 2003 S106 S116
23. K.R. Zasadny, and R.L. Wahl Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images J Nucl Med 37 1996 371 374
24. E.M. Rohren, E.K. Paulson, and R. Hagge The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer Clin Nucl Med 27 2002 550 555
25. M.M. Osman, C. Cohade, and Y. Nakamoto Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients J Nucl Med 44 2003 240 243
26. H.W. Korin, R.L. Ehman, and S.J. Riederer Respiratory kinematics of the upper abdominal organs: a quantitative study Magn Reson Med 23 1992 172 178
27. P.H. Weiss, J.M. Baker, and E.J. Potchen Assessment of hepatic respiratory excursion J Nucl Med 13 1972 758 759
28. S.A. Nehmeh, Y.E. Erdi, and C.C. Ling Effect of respiratory gating on quantifying PET images of lung cancer J Nucl Med 43 2002 876 881
29. Y. Nakamoto, B.B. Chin, and D.L. Kraitchman Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies Radiology 227 2003 817 824
30. C. Cohade, and R.L. Wahl Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements Semin Nucl Med 33 2003 228 237
31. D.L. Francis, A. Freeman, and D. Visvikis In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography Gut 52 2003 1602 1606
32. D.L. Francis, D. Visvikis, and D.C. Costa Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D- glucose in positron emission tomography for colorectal cancer Eur J Nucl Med Mol Imaging 30 2003 988 994
33. A.D. Levy Malignant liver tumors Clin Liver Dis 6 2002 147 164
34. H.B. el-Serag Epidemiology of hepatocellular carcinoma Clin Liver Dis 5 2001 87 107
35. S.D. Ryder British Society of Gastroenterology Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults Gut 52 Suppl 3 2003 iii1 iii8
36. M.S. Roh, J.S. Jeong, and Y.H. Kim Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas Hepatogastroenterology 51 2004 1315 1318
37. Y. Iwata, S. Shiomi, and N. Sasaki Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors Ann Nucl Med 14 2000 121 126
38. O. Schroder, J. Trojan, and S. Zeuzem Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection Nuklearmedizin 37 1998 279 285
39. J. Trojan, O. Schroeder, and J. Raedle Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma Am J Gastroenterol 94 1999 3314 3319
40. S. Okazumi, K. Isono, and K. Enomoto Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment J Nucl Med 33 1992 333 339
41. T. Torizuka, N. Tamaki, and T. Inokuma In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET J Nucl Med 36 1995 1811 1817
42. S. Shiomi, S. Nishiguchi, and H. Ishizu Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma Am J Gastroenterol 96 2001 1877 1880
43. Y.H. Kong, C.J. Han, and S.D. Lee Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma Korean J Hepatol 10 2004 279 287
44. J.D. Lee, M. Yun, and J.M. Lee Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography Eur J Nucl Med Mol Imaging 31 2004 1621 1630
45. A. Nakeeb, H.A. Pitt, and T.A. Sohn Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors Ann Surg 224 1996 463 473
46. R. Pichlmayr, A. Weimann, and J. Klempnauer Surgical treatment in proximal bile duct cancer: a single-center experience Ann Surg 224 1996 628 638
47. R.L. Zimmerman, F. Fogt, and M. Burke Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma Oncol Rep 9 2002 689 692
48. T. Kato, E. Tsukamoto, and Y. Kuge Clinical role of (18)F-FDG-PET for initial staging of patients with extrahepatic bile duct cancer Eur J Nucl Med Mol Imaging 29 2002 1047 1054
49. Y.J. Kim, M. Yun, and W.J. Lee Usefulness of 18F-FDG-PET in intrahepatic cholangiocarcinoma Eur J Nucl Med Mol Imaging 30 2003 1467 1472
50. A. Fritscher-Ravens, K.H. Bohuslavizki, and D.C. Broering FDG-PET in the diagnosis of hilar cholangiocarcinoma Nucl Med Commun 22 2001 1277 1285
51. C. Bartolozzi, D. Cioni, and F. Donati Focal liver lesions: MR imaging-pathologic correlation Eur Radiol 11 2001 1374 1388
52. S. Misra, A. Chaturvedi, and N.C. Misra Carcinoma of the gallbladder Lancet Oncol 4 2003 167 176
53. B. Abi-Rached, and A.I. Neugut Diagnostic and management issues in gallbladder carcinoma Oncology (Huntingt) 9 1995 19 24 [discussion: 24, 27, 30]
54. Y.W. Kim, Y.K. Park, and T.Y. Yoon Expression of the GLUT1 glucose transporter in gallbladder carcinomas Hepatogastroenterology 49 2002 907 911
55. T. Koh, H. Taniguchi, and A. Yamaguchi Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET) J Surg Oncol 84 2003 74 81
56. C.D. Anderson, M.H. Rice, and C.W. Pinson Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma J Gastrointest Surg 8 2004 90 97
57. T.E. Yaeger, and L.W. Brady Basis for current major therapies for cancer R.E. Lenhard R.T. Osteen T. Gansler The American Cancer Society's clinical oncology 2001 Blackwell Science 159 229
58. N.G. Mikhaeel, A.R. Timothy, and M.J. O'Doherty 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT Leuk Lymphoma 39 2000 543 553
59. J.W. Friedberg, A. Fischman, and D. Neuberg FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison Leuk Lymphoma 45 2004 85 92
60. K. Spaepen, S. Stroobants, and P. Dupont Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann Oncol 13 2002 1356 1363
61. W.A. Weber, K. Ott, and K. Becker Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 2001 3058 3065
62. M. Schelling, N. Avril, and J. Nahrig Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 2000 1689 1695
63. I.C. Smith, A.E. Welch, and A.W. Hutcheon Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 2000 1676 1688
64. M. Findlay, H. Young, and D. Cunningham Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil J Clin Oncol 14 1996 700 708
65. A. Dimitrakopoulou-Strauss, L.G. Strauss, and J. Rudi PET-FDG as predictor of therapy response in patients with colorectal carcinoma Q J Nucl Med 47 2003 8 13
66. G.W. Goerres, R. Stupp, and G. Barghouth The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 2005 153 162
67. J.P. McGhana, and G.D. Dodd III Radiofrequency ablation of the liver: current status AJR Am J Roentgenol 176 2001 3 16
68. T. Livraghi, S.N. Goldberg, and S. Lazzaroni Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions Radiology 218 2001 918 919
69. V. Donckier, J.L. Van Laethem, and S. Goldman [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases J Surg Oncol 84 2003 215 223
70. T. Torizuka, N. Tamaki, and T. Inokuma Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy J Nucl Med 35 1994 1965 1969
71. B.S. Langenhoff, W.J. Oyen, and G.J. Jager Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study J Clin Oncol 20 2002 4453 4458
72. H. Morikawa, S. Shiomi, and N. Sasaki Hepatocellular carcinoma monitored by F-18 fluorodeoxyglucose positron emission tomography after laparoscopic microwave coagulation therapy Clin Nucl Med 24 1999 536 538
73. G.S. Anderson, F. Brinkmann, and M.C. Soulen FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation Clin Nucl Med 28 2003 192 197
74. C.Y. Wong, R. Salem, and S. Raman Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG-PET: a comparison with CT or MRI Eur J Nucl Med Mol Imaging 29 2002 815 820
75. C.Y. Wong, R. Salem, and F. Qing Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG-PET J Nucl Med 45 2004 1892 1897
76. K. Ishiwata, K. Enomoto, and T. Sasaki A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET J Nucl Med 37 1996 279 285